In this episode, host Shikha Jain, MD, speaks with Douglas Micalizzi, MD, and Lecia Sequist, MD, about adopting novel technologies for early detection, public perception of prevention screening and more.

•    Welcome to another exciting episode of Oncology Overdrive :58
•    About Micalizzi 1:12
•    About Sequist 2:26
•    The interview 4:06
•    Sequist’s background and how she got into the screening and prevention area of oncology 4:21
•    Micalizzi on his chemistry background and how he got into this space 8:03
•    About the evolution of early detection and MGH’s Cancer Early Detection and Diagnostics Clinic 11:47
•    Who is involved in this clinic and how do you handle a patient’s panic over seeing cancer specialists? 14:30
•    Discussion on the New York Times article Not Everything We Call Cancer Should Be Called Cancer and nomenclatures surrounding the various cancer stages and types 19:29
•    Public perception of screening and the “push” from people outside of medicine 28:49
•    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 36:31
•    How to contact Micalizzi and Sequist 37:51
•    Thanks for listening 39:14

Douglas Micalizzi, MD, is a medical oncologist at Massachusetts General Hospital specializing in breast cancer, early cancer detection and hereditary cancer risk.

Lecia V. Sequist, MD, MPH, is currently the Landry Family Professor of Medicine at Harvard Medical School, the Program Director for Cancer Early Detection and Diagnostics at MGH and the leader of the Cancer Risk, Prevention and Early Detection Program at the joint Dana-Farber/Harvard Cancer Center.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Micalizzi and Sequist can be reached through the Massachusetts General Hospital Cancer Early Detection and Diagnostics Clinic webpage. Sequist can also be reached on X, formerly known as Twitter @LeciaSequist.
 
Disclosures:  Jain and Micalizzi report no relevant financial disclosures. Sequist reports her institution has received funds related to clinical trials from AstraZeneca, Delfi Diagnostics and Novartis.